D. Ross Camidge, M.D., Ph.D., University of Colorado Cancer Center
PHOTO CREDIT: University of Colorado Cancer Center

Clinical trials of new anti-cancer therapies have often excluded patients whose disease has spread to the brain or central nervous system (CNS), which could include half to two-thirds of the stage IV population in some cancer types. An international group has published new trial design guidelines (D. Ross Camidge, M.D. lead author) on how to address cancer patients with CNS involvement within clinical trials of anti-cancer drugs, which could represent a turning point in cancer drug development. (EurekAlert)